QPPV.COM KNOWLEDGE ASSESSMENT

WHODrug Coding in Pharmacovigilance: Professional Knowledge Assessment

Test your understanding of the concepts covered by WHODrug Coding in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A reporter says a patient takes 30 mg of a medicine each day but does not identify the strength of each tablet or unit. Which action is most appropriate?
Question 2 of 10 A patient develops an adverse event after taking one product and receives a different medicine to treat the event. Which interpretation is most appropriate?
Question 3 of 10 An organisation is planning a WHODrug version transition. Which governance approach is most appropriate?
Question 4 of 10 A safety database contains the same product exposure under different levels of specificity because cases were coded using different WHODrug releases. What is the most appropriate analytical response?
Question 5 of 10 An analyst wants to compare a product-specific safety pattern with a pattern shared across several brands containing the same substance. What is a key analytical implication of WHODrug structure?
Question 6 of 10 A short trade name appears in WHODrug for products with different ingredients in different countries. The case contains no country or other distinguishing detail. What should the coder do?
Question 7 of 10 A patient is reported to have taken one fixed-dose product containing substances A and B. Which coding approach best preserves the exposure information?
Question 8 of 10 A safety reviewer is assessing an ICSR and needs to distinguish the roles of WHODrug and MedDRA. Which interpretation is most accurate?
Question 9 of 10 A report identifies a trade product, its country, form and strength. How should a coder generally choose between B3 and C3 when the system supports both?
Question 10 of 10 A case initially describes a medicine only as an 'antibiotic.' Follow-up identifies its exact brand and formulation. What should happen to the product coding?

Select an answer to continue.

QPPV.com